CN103417472B - 用于治疗耳部病症的控制释放皮质类固醇组合物和方法 - Google Patents

用于治疗耳部病症的控制释放皮质类固醇组合物和方法 Download PDF

Info

Publication number
CN103417472B
CN103417472B CN201310289183.9A CN201310289183A CN103417472B CN 103417472 B CN103417472 B CN 103417472B CN 201310289183 A CN201310289183 A CN 201310289183A CN 103417472 B CN103417472 B CN 103417472B
Authority
CN
China
Prior art keywords
formulation
formulations
dexamethasone
corticosteroid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310289183.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103417472A (zh
Inventor
杰伊·利希特尔
贝内迪克特·福尔拉特
安德鲁·M·特拉梅尔
塞尔希奥·G·杜龙
法布里斯·皮乌
路易斯·A·德拉玛丽
叶强
卡尔·勒贝尔
迈克尔·克里斯托弗·斯凯夫
杰弗里·P·哈里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otonomy Inc
University of California San Diego UCSD
Original Assignee
Otonomy Inc
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41319223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103417472(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0823378A external-priority patent/GB2459910B/en
Application filed by Otonomy Inc, University of California San Diego UCSD filed Critical Otonomy Inc
Publication of CN103417472A publication Critical patent/CN103417472A/zh
Application granted granted Critical
Publication of CN103417472B publication Critical patent/CN103417472B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201310289183.9A 2008-05-14 2009-05-14 用于治疗耳部病症的控制释放皮质类固醇组合物和方法 Expired - Fee Related CN103417472B (zh)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US12771308P 2008-05-14 2008-05-14
US61/127,713 2008-05-14
US6042508P 2008-06-10 2008-06-10
US61/060,425 2008-06-10
US7458308P 2008-06-20 2008-06-20
US61/074,583 2008-06-20
US8245008P 2008-07-21 2008-07-21
US61/082,450 2008-07-21
US8794008P 2008-08-11 2008-08-11
US61/087,940 2008-08-11
US9438408P 2008-09-04 2008-09-04
US61/094,384 2008-09-04
US9524808P 2008-09-08 2008-09-08
US61/095,248 2008-09-08
US10111208P 2008-09-29 2008-09-29
US61/101,112 2008-09-29
US14003308P 2008-12-22 2008-12-22
US61/140,033 2008-12-22
GB0823378A GB2459910B (en) 2008-04-21 2008-12-22 Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders
GB0823378.5 2008-12-22
CN200980116869XA CN102026623B (zh) 2008-05-14 2009-05-14 用于治疗耳部病症的控制释放皮质类固醇组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200980116869XA Division CN102026623B (zh) 2008-05-14 2009-05-14 用于治疗耳部病症的控制释放皮质类固醇组合物和方法

Publications (2)

Publication Number Publication Date
CN103417472A CN103417472A (zh) 2013-12-04
CN103417472B true CN103417472B (zh) 2018-01-02

Family

ID=41319223

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310289183.9A Expired - Fee Related CN103417472B (zh) 2008-05-14 2009-05-14 用于治疗耳部病症的控制释放皮质类固醇组合物和方法
CN200980116869XA Expired - Fee Related CN102026623B (zh) 2008-05-14 2009-05-14 用于治疗耳部病症的控制释放皮质类固醇组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200980116869XA Expired - Fee Related CN102026623B (zh) 2008-05-14 2009-05-14 用于治疗耳部病症的控制释放皮质类固醇组合物和方法

Country Status (14)

Country Link
US (9) US8030297B2 (https=)
EP (1) EP2303227B1 (https=)
JP (3) JP5551685B2 (https=)
KR (2) KR101534422B1 (https=)
CN (2) CN103417472B (https=)
AU (1) AU2009246870B2 (https=)
BR (1) BRPI0912482A2 (https=)
CA (1) CA2723458C (https=)
IL (2) IL208806A (https=)
MX (1) MX2010012397A (https=)
MY (1) MY161021A (https=)
RU (2) RU2469726C2 (https=)
WO (1) WO2009139924A2 (https=)
ZA (1) ZA201007482B (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130079749A1 (en) * 2007-08-29 2013-03-28 Advanced Bionics, Llc Modular Drug Delivery System for Minimizing Trauma During and After Insertion of a Cochlear Lead
EP2249921B1 (en) 2008-02-25 2020-06-17 Eyegate Pharmaceuticals, Inc. Enhanced delivery of dexamethasone phosphate to ocular tissues through iontophoresis
KR20130097813A (ko) * 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
KR101534422B1 (ko) * 2008-05-14 2015-07-09 오토노미, 인코포레이티드 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법
US8648119B2 (en) * 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US20100016218A1 (en) * 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
JP5421366B2 (ja) * 2008-07-21 2014-02-19 オトノミ―，インク． 制御放出性の耳の構造体調節および生来の免疫システム調節化合物および耳の障害の処置のための方法
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8496957B2 (en) * 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8399018B2 (en) * 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
CA2751761A1 (en) 2008-10-22 2010-04-29 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
JP6013736B2 (ja) * 2008-12-22 2016-10-25 オトノミ—，インク． 耳の障害の処置のための耳感覚細胞モジュレータ組成物の制御放出及びその方法
US20140076336A1 (en) * 2009-09-17 2014-03-20 Ascentia Health, Inc. Ear insert for relief of tmj discomfort and headaches
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
WO2011049958A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
EP2675409A4 (en) * 2011-02-18 2015-04-08 Otonomy Inc PREVENTING AND RESTORING MEDICAMENT-INDUCED OTOTOXICITY
US20140142191A1 (en) * 2011-07-20 2014-05-22 Theracoat Ltd. Production of thermoreversible hydrogels for therapeutic applications
PT2773325T (pt) * 2011-11-04 2018-12-19 Enceladus Pharmaceuticals B V Corticosteróides lipossômicos para o tratamento de transtornos inflamatórios em humanos
CA2862406C (en) 2012-01-10 2024-06-18 Entrx LLC Otic formulations, methods and devices
CA2883896C (en) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
CN104822965B (zh) 2012-10-12 2017-11-28 利滕斯汽车合伙公司 通过环形传动构件由mgu或马达辅助或起动的发动机所使用的隔离器
US9849126B2 (en) 2013-01-03 2017-12-26 Entrx LLC Sterile otic formulations
TWI624262B (zh) * 2013-01-23 2018-05-21 桑紐爾製藥公司 醫藥配方
USRE48077E1 (en) 2013-02-28 2020-07-07 Anida Pharma Inc. Methods of treating ototoxicity
US20160074322A1 (en) * 2013-04-25 2016-03-17 Seachaid Pharmaceuticals, Inc. Oral cefepime compositions and uses thereof
DK3035849T3 (da) 2013-08-21 2019-09-30 Senseonics Inc Lægemiddeleluering til beskyttelse in vivo af biosensor-analysander
US9486405B2 (en) 2013-08-27 2016-11-08 Otonomy, Inc. Methods for the treatment of pediatric otic disorders
CN103751779A (zh) * 2014-02-25 2014-04-30 中国农业科学院上海兽医研究所 O型口蹄疫多肽的泊洛沙姆凝胶佐剂
CN104644545A (zh) * 2015-02-27 2015-05-27 苏州丝美特生物技术有限公司 一种治疗内耳疾病的控释缓释丝素蛋白凝胶制剂
KR101628707B1 (ko) * 2014-05-29 2016-06-10 한남대학교 산학협력단 난청 치료용 약물 전달 시스템 및 이의 제조방법
US20170216439A1 (en) * 2014-07-29 2017-08-03 Otonomy, Inc. Otic formulations for the treatment of ceruminosis
FR3024361B1 (fr) * 2014-07-30 2017-11-24 Affichem Utilisation de derives de sterols pour traitement de la perte auditive neurosensorielle et composition correspondante
TWI674899B (zh) 2015-01-21 2019-10-21 美商桑紐爾製藥公司 醫藥配方
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
TWI773641B (zh) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
CA2993645A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
WO2017119928A1 (en) 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long acting injectable formulations
WO2018193423A1 (en) * 2017-04-21 2018-10-25 Ferring B.V. Oral pharmaceutical compositions of corticosteroids
PL3641728T3 (pl) * 2017-06-23 2021-09-20 Laboratorios Salvat, S.A. Kompozycja klobetazolu w postaci nanoemulsji typu olej w wodzie
WO2019066505A1 (ko) * 2017-09-29 2019-04-04 주식회사 엘지화학 히알루론산 기반 하이드로겔 약제학적 안정화 조성물 및 그 제조방법
KR20190038368A (ko) * 2017-09-29 2019-04-08 주식회사 엘지화학 히알루론산 기반 하이드로겔 약제학적 안정화 조성물 및 그 제조방법
CN107823636A (zh) * 2017-12-14 2018-03-23 阜阳市平衡医疗保健器械有限公司 一种治疗耳鸣的药物
CN108403628B (zh) * 2018-05-21 2021-01-08 北京和舆医药科技有限公司 一种地塞米松磷酸钠注射剂
CN113271979A (zh) 2018-10-24 2021-08-17 费灵有限公司 皮质类固醇的粘膜粘附性药物组合物
WO2020092897A1 (en) 2018-11-02 2020-05-07 Senseonics, Incorporated Drug eluting matrix on analyte indicator
US20220062498A1 (en) * 2018-12-21 2022-03-03 Qmark Medical Inc. Hydrogel composition for mucosal lifting procedures within lumenal anatomical structures
US20200214976A1 (en) 2019-01-09 2020-07-09 Spiral Therapeutics, Inc. Self-gelling solutions for administration of therapeutics to the inner ear
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
EP3930808A4 (en) 2019-02-27 2022-12-14 Oticara, Inc. METHODS OF TREATMENT OF NASAL, SINONASAL AND NASOPHARYNGEAL TISSUE INFECTION AND/OR INFLAMMATION
US12390510B2 (en) 2019-05-29 2025-08-19 Massachusetts Eye And Ear Infirmary Methods of treating sensorineural hearing loss using fibroblast growth factor 2 (FGF2)
KR102425971B1 (ko) * 2020-06-02 2022-07-28 충남대학교산학협력단 덱사메타손 및 소듐 카프르산을 포함하는 내이 전달용 조성물
CA3188400A1 (en) * 2020-08-03 2022-02-10 Daniel S. Kohane Thermo-sensitive permeation enhancing formulations for drug delivery
JP7825562B2 (ja) * 2020-09-25 2026-03-06 アステラス製薬株式会社 耳内投与用の医薬組成物
EP4279061A1 (en) * 2022-05-18 2023-11-22 Acousia Therapeutics GmbH Aqueous gel composition
KR102927998B1 (ko) * 2022-12-09 2026-02-20 가톨릭대학교 산학협력단 약물　전달용 조성물 및 이의 용도
AU2024354209A1 (en) * 2023-09-28 2026-02-26 Syntis Bio, Inc. Synergistic permeation enhancers for gastrointestinal synthetic epithelial linings

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089490A1 (en) * 2006-01-27 2007-08-09 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
IT1251151B (it) * 1991-08-05 1995-05-04 Fidia Spa Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ES2141775T3 (es) * 1993-04-16 2000-04-01 Wakamoto Pharma Co Ltd Composicion medicinal a base de agua termicamente gelificante reversible.
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
WO1995015152A1 (en) 1993-11-30 1995-06-08 Zenichi Ogita External preparation
JP3696265B2 (ja) 1994-02-04 2005-09-14 日本オルガノン株式会社 点鼻液剤
ATE317690T1 (de) 1994-04-08 2006-03-15 Qlt Usa Inc Flüssige zusammensetzungen zur arzneistoffabgabe
JPH11510837A (ja) 1995-07-28 1999-09-21 フォーカル，インコーポレイテッド 薬物送達のための制御された放出薬剤および組織処置薬剤としての使用のためのマルチブロック生分解性ヒドロゲル
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
WO1997038698A1 (en) 1996-04-18 1997-10-23 University Technology Corporation Methods for treating middle and inner ear disorders
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
NL1004214C2 (nl) * 1996-10-07 1998-04-10 Avebe Coop Verkoop Prod Toepassing van gemodificeerd zetmeel als middel voor het vormen van een thermoreversibele gel.
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
TR200001117T2 (tr) 1997-10-22 2000-09-21 Ponikau Jens Mukozal dokudaki enflomasyonu önlemek ve tedavi etmek için maddeler ve yöntemler.
DE19748763A1 (de) 1997-11-05 1999-05-06 Hans Peter Zenner Verwendung von Vasopressin-Antagonisten
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6649621B2 (en) 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6177434B1 (en) 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
EP1039932A1 (en) 1997-12-23 2000-10-04 Alliance Pharmaceutical Corporation Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
WO2000007603A2 (en) 1998-08-04 2000-02-17 Madash Llp End modified thermal responsive hydrogels
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
EP1158957A4 (en) 1999-02-24 2004-12-15 Dong Wha Pharm Ind Co Ltd LIQUID SUPPOSITORIAL COMPOSITION OF DICLOFENAC SODIUM
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
WO2001022936A1 (en) * 1999-09-24 2001-04-05 Alcon Universal Ltd. Topical suspension formulations containing ciprofloxacin and dexamethasone
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
MXPA02008966A (es) 2000-03-14 2003-02-12 Alcon Inc Viscoelasticos para uso en cirugia del oido medio.
AU2001251011A1 (en) * 2000-03-27 2001-10-08 The General Hospital Corporation Treatments for immune-mediated ear disorders
US6998137B2 (en) 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
DE10346940B3 (de) 2003-10-06 2005-06-16 Schering Ag Substituierte Pentanole, ihre Verwendung zur Herstellung von Arzneimitteln speziell Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
SE0100158D0 (sv) 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
US20060269602A1 (en) 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
TWI324925B (en) * 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
US6488952B1 (en) 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
RU2295346C2 (ru) * 2001-09-21 2007-03-20 Алькон, Инк. Способ лечения инфекций среднего уха
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
DE10162593A1 (de) 2001-12-19 2003-07-03 Menarini Ricerche Spa Stabilisierte topische Brivudin-Formulierungen
US20030229333A1 (en) 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
US20060013858A1 (en) * 2002-10-29 2006-01-19 Trune Dennis R Fludrocortisone treatment for hearing loss
US20040101506A1 (en) 2002-11-25 2004-05-27 Fust Charles A. Composition for the prevention and treatment of inflammation of the ear
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2004093870A1 (en) 2003-03-20 2004-11-04 Pharmacia Corporation Treatment and prevention of otic disorders
WO2005046438A2 (en) 2003-11-06 2005-05-26 Pluromed, Inc. Internal clamp for surgical procedures
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) * 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8870826B2 (en) 2004-05-24 2014-10-28 Auris Medical Llc Combined otic aspirator and medication dispenser
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
AU2005282571A1 (en) 2004-09-03 2006-03-16 Piedmont Pharmaceuticals, Llc Methods for transmembrane treatment and prevention of otitis media
JP2006111585A (ja) 2004-10-15 2006-04-27 Mebiol Kk 徐放性組成物およびその徐放方法
US20060264897A1 (en) * 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
EP1858506A2 (en) 2005-03-10 2007-11-28 3M Innovative Properties Company Methods of treating ear infections
MX2007011502A (es) * 2005-03-16 2007-12-07 Elan Pharma Int Ltd Formulaciones de antagonista del receptor de leucotrieno en nanoparticulas con corticosteroide.
WO2006102964A2 (en) * 2005-03-29 2006-10-05 Evonik Röhm Gmbh Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
EP1893174A2 (en) 2005-05-10 2008-03-05 Cytophil, Inc. Injectable hydrogels and methods of making and using same
KR101041843B1 (ko) 2005-07-30 2011-06-17 삼성엘이디 주식회사 질화물계 화합물 반도체 발광소자 및 그 제조방법
US20070048338A1 (en) 2005-08-26 2007-03-01 Ladd Byron S Compositions and methods for surface treatment in medical and surgical procedures
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2007037886A2 (en) 2005-09-26 2007-04-05 Piedmont Pharmaceuticals Llc Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into the middle ear
CA2622001A1 (en) 2005-09-26 2007-04-05 Piedmont Pharmaceuticals Llc Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear
ES2524994T3 (es) 2005-09-28 2014-12-16 Auris Medical Ag Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
US20070110788A1 (en) 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
FR2894585B1 (fr) 2005-12-14 2012-04-27 Rhodia Recherches Et Tech Copolymere comprenant des unites zwitterioniques et d'autres unites, composition comprenant le copolymere, et utilisation
WO2008001341A1 (en) 2006-06-27 2008-01-03 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
WO2008049196A1 (en) 2006-10-27 2008-05-02 Iomedix Development International Srl Composition for improving blood cholesterol levels
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
JP2010512230A (ja) 2006-12-11 2010-04-22 プルーロームド インコーポレイテッド 灌流臓器止血法
WO2008131439A1 (en) 2007-04-23 2008-10-30 House Ear Institute Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7
US7795231B2 (en) 2007-10-04 2010-09-14 Insite Vision Incorporated Concentrated aqueous azalide formulations
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
KR101534422B1 (ko) 2008-05-14 2015-07-09 오토노미, 인코포레이티드 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법
US8822410B2 (en) 2008-05-19 2014-09-02 Children's Medical Center Corporation Tympanic membrane permeating ear drops and uses thereof
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US20100016218A1 (en) 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
AU2009274137B2 (en) 2008-07-21 2013-10-31 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US20100016450A1 (en) 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
JP5421366B2 (ja) 2008-07-21 2014-02-19 オトノミ―，インク． 制御放出性の耳の構造体調節および生来の免疫システム調節化合物および耳の障害の処置のための方法
CN101664381A (zh) 2009-08-21 2010-03-10 天津生机集团股份有限公司 治疗奶牛乳房炎的原位凝胶缓释制剂的制备方法
WO2011049958A2 (en) 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
ES2369101B2 (es) 2010-05-07 2012-08-02 Universidade De Santiago De Compostela Sistema farmacéutico acuoso para la administración de fármacos en las uñas.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089490A1 (en) * 2006-01-27 2007-08-09 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
《地塞米松磷酸钠温度敏感原位凝胶的特性研究》;李欣宇等;《药学学报》;20081231;第43卷(第2期);全文 *
《治疗耳聋的地塞米松原位凝胶给药系统的研究》;陈钢等;《中国药学杂志》;20060531;第41卷(第9期);第686页右栏2.1 *

Also Published As

Publication number Publication date
KR20100135321A (ko) 2010-12-24
US8546363B2 (en) 2013-10-01
US20140364403A1 (en) 2014-12-11
JP6014069B2 (ja) 2016-10-25
IL208806A0 (en) 2011-01-31
KR101477329B1 (ko) 2014-12-29
EP2303227A2 (en) 2011-04-06
KR20130100017A (ko) 2013-09-06
US20110319377A1 (en) 2011-12-29
EP2303227B1 (en) 2021-10-06
MY161021A (en) 2017-03-31
IL208806A (en) 2016-02-29
US20110008456A1 (en) 2011-01-13
CN102026623B (zh) 2013-08-14
JP2011529854A (ja) 2011-12-15
IL244103A0 (en) 2016-04-21
US20180110727A1 (en) 2018-04-26
BRPI0912482A2 (pt) 2020-08-18
WO2009139924A2 (en) 2009-11-19
MX2010012397A (es) 2011-03-15
US20100009952A1 (en) 2010-01-14
HK1156533A1 (en) 2012-06-15
JP5551685B2 (ja) 2014-07-16
CN102026623A (zh) 2011-04-20
RU2012139802A (ru) 2014-03-27
US8030297B2 (en) 2011-10-04
US20110319375A1 (en) 2011-12-29
CA2723458C (en) 2014-01-28
CN103417472A (zh) 2013-12-04
EP2303227A4 (en) 2012-10-31
US8680082B2 (en) 2014-03-25
US20110319374A1 (en) 2011-12-29
US20150313838A1 (en) 2015-11-05
WO2009139924A3 (en) 2010-04-01
ZA201007482B (en) 2012-01-25
US8658626B2 (en) 2014-02-25
US8680083B2 (en) 2014-03-25
AU2009246870A1 (en) 2009-11-19
US9511020B2 (en) 2016-12-06
US20110319373A1 (en) 2011-12-29
US8828980B2 (en) 2014-09-09
JP2016153423A (ja) 2016-08-25
JP2014101392A (ja) 2014-06-05
RU2469726C2 (ru) 2012-12-20
AU2009246870B2 (en) 2013-08-01
CA2723458A1 (en) 2009-11-19
US9744126B2 (en) 2017-08-29
KR101534422B1 (ko) 2015-07-09
RU2010150863A (ru) 2012-06-20

Similar Documents

Publication Publication Date Title
CN103417472B (zh) 用于治疗耳部病症的控制释放皮质类固醇组合物和方法
JP5903119B2 (ja) 耳の不調の治療用の制御放出性の抗菌性組成物および方法
GB2459910A (en) Sustained release corticosteroid compositions for treatment of otic disorders
TWI382839B (zh) 控制釋放之皮質類固醇組成物及其用於耳部失調治療的方法
HK1156533B (en) Controlled release corticosteroid compositions and methods for the treatment of otic disorders
HK1191867A (en) Controlled release corticosteroid compositions and methods for the treatment of otic disorders
HK1191867B (en) Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1191867

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1191867

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180102

Termination date: 20210514

CF01 Termination of patent right due to non-payment of annual fee